Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two …
R Wahid, LD Mercer, T De Leon, R DeAntonio… - The Lancet …, 2022 - thelancet.com
Background Sabin strains used in oral poliovirus vaccines (OPV) can revert to virulence and,
in rare instances, cause disease or generate vaccine-derived strains leading to outbreaks in …
in rare instances, cause disease or generate vaccine-derived strains leading to outbreaks in …
Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial
X Sáez-Llorens, R Clemens… - The Lancet Infectious …, 2016 - thelancet.com
Background Following the proposed worldwide switch from trivalent oral poliovirus vaccine
(tOPV) to bivalent types 1 and 3 OPV (bOPV) in 2016, inactivated poliovirus vaccine (IPV) …
(tOPV) to bivalent types 1 and 3 OPV (bOPV) in 2016, inactivated poliovirus vaccine (IPV) …
Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two …
I De Coster, I Leroux-Roels, AS Bandyopadhyay… - The Lancet, 2021 - thelancet.com
Background Two novel type 2 oral poliovirus vaccine (OPV2) candidates, novel OPV2-c1
and novel OPV2-c2, designed to be more genetically stable than the licensed Sabin …
and novel OPV2-c2, designed to be more genetically stable than the licensed Sabin …
Type 2 poliovirus detection after global withdrawal of trivalent oral vaccine
IM Blake, M Pons-Salort, NA Molodecky… - … England Journal of …, 2018 - Mass Medical Soc
Background Mass campaigns with oral poliovirus vaccine (OPV) have brought the world
close to the eradication of wild poliovirus. However, to complete eradication, OPV must itself …
close to the eradication of wild poliovirus. However, to complete eradication, OPV must itself …
Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6–9 months in Moradabad, India: a community-based, randomised controlled trial
CF Estívariz, H Jafari, RW Sutter, TJ John… - The Lancet infectious …, 2012 - thelancet.com
Background The continued presence of polio in northern India poses challenges to the
interruption of wild poliovirus transmission and the management of poliovirus risks in the …
interruption of wild poliovirus transmission and the management of poliovirus risks in the …
Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin …
Background Replacement of the trivalent oral poliovirus vaccine (tOPV) with bivalent types 1
and 3 oral poliovirus vaccine (bOPV) and global introduction of inactivated poliovirus …
and 3 oral poliovirus vaccine (bOPV) and global introduction of inactivated poliovirus …
Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021
A Mirzoev, GR Macklin, Y Zhang, BA Mainou… - The Lancet Global …, 2022 - thelancet.com
Background Novel oral poliovirus vaccine type 2 (nOPV2) was used to control an outbreak
of type 2 circulating vaccine derived poliovirus (cVDPV2) in Tajikistan, in 2021. We …
of type 2 circulating vaccine derived poliovirus (cVDPV2) in Tajikistan, in 2021. We …
Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India
NC Grassly, H Jafari, S Bahl, S Durrani… - The Journal of …, 2009 - academic.oup.com
Background Persistent wild-poliovirus transmission, particularly in India, has raised
questions about the degree of mucosal immunity induced by oral poliovirus vaccine (OPV) in …
questions about the degree of mucosal immunity induced by oral poliovirus vaccine (OPV) in …
Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label …
M O'Ryan, AS Bandyopadhyay, R Villena… - The Lancet Infectious …, 2015 - thelancet.com
Background Bivalent oral poliovirus vaccine (bOPV; types 1 and 3) is expected to replace
trivalent OPV (tOPV) globally by April, 2016, preceded by the introduction of at least one …
trivalent OPV (tOPV) globally by April, 2016, preceded by the introduction of at least one …
[HTML][HTML] Immunogenicity of poliovirus vaccines in chronically malnourished infants: a randomized controlled trial in Pakistan
Reaching high population immunity against polioviruses (PV) is essential to achieving
global polio eradication. Efficacy of oral poliovirus vaccine (OPV) varies and is lower among …
global polio eradication. Efficacy of oral poliovirus vaccine (OPV) varies and is lower among …